2025年12月31日，原子高科也披露了子公司海得威补税事项。原子高科方面表示，预计上述事项将影响 公司2025年度归母净利润为0.54亿元。 中经记者 晏国文 卢志坤 北京报道 2025年上半年，中国同辐营业收入为28.58亿元，同比增长1.7%；净利润为3.41亿元，同比增长11.2%。 海得威2024年营业收入为23.54亿元，净利润为5.26亿元。 2025年12月31日，港股上市公司中国同辐（1763.HK）披露，旗下非全资附属公司深圳市中核海得威生 物科技有限公司（以下简称"海得威"）近日补缴2024年企业所得税、增值税等1.88亿元及滞纳金，合计 为2.71亿元。 中国同辐方面称，该事项将影响中国同辐2025年利润约1.3亿元。 （编辑：曹学平 审核：童海华 校对：翟军） ...

智通财经APP讯，中国同辐(01763)发布公告，于2025年12月31日，经相关主管机关认定，公司非全资附 属公司深圳市中核海得威生物科技有限公司(海得威)近日应补缴2021年1月1日至2024年12月31日企业所 得税、增值税等税款人民币1.88亿元及滞纳金合计人民币2.71亿元，主要涉及海得威前述年度期间的销 售费用、存货非正常损失等，该事项不涉及行政处罚。截至本公告日期，海得威已完成该税款缴纳。预 期该涉税事项将影响2025年度的权益股东应占年内利润约人民币1.30亿元，但与该结付有关的实际财务 影响将视公司独立核数师的审阅及审核结果而定。 此外，公司对上述事项高度重视，将进一步提高自身的管理能力，切实维护公司及股东利益。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資 者，於2025年12月31日，經相關主管機關認定，本公司之非全資附屬公司深圳 市中核海得威生物科技有限公司（「海得威」）近日應補繳2021年1月1日至2024年 12月31日企業所得稅、增值稅等稅款人民幣1.88億元及滯納金合計人民幣2.71億 元，主要涉及海得威前述年度期間的銷售費用、存貨非正常損失等，該事項不涉 及行政處罰。 截至本公告日期，海得威已完成該稅款繳納。預期該涉稅事項將影響2025年度的 權益股東應佔年內利潤約人民幣1.30億元，惟與該結付有關的實際財務影響將視 乎本公司獨立核數師的審閱及審核結果而定。 本公司對上述事項高度重視，將進一步提高自身的管理能力，切實維護公司 ...

智通财经APP获悉，2025年12月31日，港股上市公司投资日志如下： | 类别 | 公司 | | --- | --- | | | 智谱 | | | (招股中) | | | 天数智芯 | | 新股活动 | (招股中) | | | 精锋医疗-B | | | (招股中) | | | 创辉珠宝 | | | 鸿盛昌资源 | | | 中国海洋发展 亚洲电视控股 | | | 汇隆控股 | | 业绩公布日 | 大众金融控股 | | | 泰锦控股 | | | 濠亮环球 | | | INTL GENIUS | | | 黄河实业 | | | 维亮控股 | | | 赛力斯 | | | 清晰医疗 | | | 高山企业 | | | 加和国际控股 | | 股东大会召开日 | 宋都服务 | | | 佑驾创新 | | | 汇舸环保 | | | 天臣控股 | | | 十方控股 | | | 鸿伟亚洲 | | 停复牌 | （复牌） | | 分红派息 | 完美医疗 | | | （派息日） | | | 义合控股 | | | （派息日） | | | 大快活集团 | | | （派息日） | | | 嘉利国际 | | | （派息日） | | | 富士高实业 ...

Market Overview - The Hong Kong stock market experienced fluctuations on December 22, with the Hang Seng Index rising by 0.43% to close at 25,801.77 points, the Hang Seng Tech Index increasing by 0.87% to 5,526.83 points, and the National Enterprises Index up by 0.43% to 8,939.68 points [1] - Major technology stocks showed mixed performance, with Alibaba up by 0.76%, Tencent Holdings up by 0.08%, and JD Group up by 0.9%, while Xiaomi fell by 1.83% and NetEase by 0.09% [1] - The optical communication sector was strong, with Huiju Technology rising by 13% and Changfei Optical Fiber Cable up by 11% [1] - Duty-free concept leader China Duty Free Group surged over 15%, while the new consumption sector saw significant gains, with Mixue Group up over 10% and Pop Mart up over 4% [1] - Chip stocks also rose, with SMIC increasing by nearly 6% and Hua Hong Semiconductor up over 5% [1] - Gold stocks generally rose, with China National Gold up over 7% and Shandong Gold up over 5% [1] - Four new stocks were listed, including Impression Dahongpao and Huacheng Biotechnology, all of which experienced a decline in their initial trading [1] Company News - SF Holding reported a total revenue of 27.173 billion yuan for November, a year-on-year increase of 7.85%, with express logistics revenue growing by 9.88% and business volume increasing by 20.13% [2] - Capital Venture expects to achieve an unaudited net profit of approximately 115 million to 140 million HKD for the fiscal year ending September 30, 2025, marking a turnaround from losses, primarily due to improved performance in listed equity investments [2] - Tianqi Lithium announced the completion of the third phase of its chemical-grade lithium concentrate expansion project, which has officially commenced trial production [3] - Qingdao Port plans to purchase two assets from the cruise port development for the Qingdao Shipping Financial Center [4] - CanSino Biologics has initiated Phase I clinical trials for its DTCP–HIb–MCV4 combined vaccine, completing the enrollment of the first subject [5] - Junshi Biosciences received FDA approval for the Phase I clinical trial application of its biosimilar HLX18 for the treatment of various solid tumors [5] - China National Nuclear Corporation's subsidiary, CNNC Haidewei, received clinical approval for its BNCT boron drug [6] - Hisense Home Appliances subscribed to a financial product from Jingu Trust worth 1.892 billion yuan [7] - Evergrande Property's liquidator has received several updated non-binding offers from selected bidders, which are currently under consideration [7] - Ruian Construction completed the sale of Ruian Property Management Services [8] - Tianjin Port Development's subsidiary plans to purchase ten gantry cranes for 185 million yuan [9] Institutional Insights - CITIC Securities noted that after a strong rally in September, the Hong Kong market has experienced fluctuations since October due to varying overseas macro expectations, with quality assets becoming more attractive [10] - Huatai Securities indicated that the market is still in a left-side layout phase, with uncertainties surrounding the "Santa rally" and potential supply-demand pressures at year-end [10] - China Galaxy suggested focusing on the technology sector as a long-term investment theme, which has seen valuation corrections and may rebound due to multiple favorable factors [10] - The consumption sector is expected to receive significant policy support, with current valuations at relatively low levels, indicating potential for long-term growth [10]

12月22日，港股股指高开冲高后大幅回撤，午前再度震荡上行，截止午盘，恒生指数涨0.2%报25742.24 点，恒生科技指数涨0.89%报5528.05点，国企指数涨0.27%报8925.39点，红筹指数涨0.37%报4066.49 点。 盘面上，大型科技股走势分化，阿里巴巴涨0.83%，腾讯控股跌0.08%，京东集团涨0.99%，小米集团跌 2.12%，网易跌0.75%，美团跌0.1%，快手涨0.6%，哔哩哔哩涨0.73%；芯片股走强，中芯国际涨超 7%，华虹半导体涨逾5%；黄金股普涨，灵宝黄金、中国黄金国际涨超6%，山东黄金、赤峰黄金涨逾 4%；新消费概念多数上涨，蜜雪集团涨超9%；今日四只新股上市，印象大红袍、华芢生物、明基医 院、南华期货挂牌，集体破发。 企业新闻 顺丰控股(06936.HK)：11月速运物流业务、供应链及国际业务合计收入为271.73亿元，同比增长 7.85%。其中速运物流业务收入同比增长9.88%，业务量同比增长20.13%。 首都创投(02324.HK)：预计截至2025年9月30日止年度(本年度)取得未经审核综合净溢利约1.15亿港元至 1.4亿港元，同比扭亏。主要由于上市股权 ...

Market Overview - The Hong Kong stock market opened higher on December 22, with the Hang Seng Index rising by 0.41% to 25,795.94 points, the Hang Seng Tech Index increasing by 0.61% to 5,512.54 points, and the State-Owned Enterprises Index up by 0.49% to 8,944.74 points [1] - Major technology stocks mostly rose, with Alibaba up by 0.48%, Tencent Holdings up by 0.98%, and Meituan up by 1.46% [1] - The smart driving concept stocks saw significant gains, with Xiaoma Zhixing rising over 6% [1] - Gold stocks experienced a general increase, with Lingbao Gold rising over 2% [1] - Chip stocks were active, with SMIC rising over 1% [1] Company News - SF Holding (06936.HK) reported a total revenue of 27.173 billion yuan for November, a year-on-year increase of 7.85%, with express logistics revenue growing by 9.88% and business volume increasing by 20.13% [2] - Capital Investment (02324.HK) expects to achieve an unaudited consolidated net profit of approximately 115 million to 140 million HKD for the fiscal year ending September 30, 2025, marking a turnaround from losses due to improved performance in listed equity investments [2] - Tianqi Lithium (09696.HK) announced the completion of the third phase of its chemical-grade lithium concentrate expansion project [3] - Qingdao Port (06198.HK) plans to purchase two assets from the cruise port development for the Qingdao Shipping Financial Center [4] - CanSino Biologics (06185.HK) has initiated Phase I clinical trials for the DTCP–HIb–MCV4 combined vaccine [5] - China National Nuclear Corporation's subsidiary, CNNC Haidewei, received clinical approval for BNCT boron drugs [6] Investment Insights - CITIC Securities noted that after a period of single-sided growth in September, the Hong Kong stock market has experienced fluctuations since October, with quality assets entering a high-value zone [14] - Changjiang Securities highlighted that the approval of the first batch of L3-level vehicles marks a new stage for smart connected vehicles in mass production, suggesting investment opportunities in smart driving algorithm providers and related hardware suppliers [14][15]

Company News - SF Holding (06936.HK) reported a total revenue of 27.173 billion yuan for its express logistics, supply chain, and international business in November, representing a year-on-year growth of 7.85%. The express logistics business revenue grew by 9.88%, with a business volume increase of 20.13% [2] - Capital Investment (02324.HK) expects to achieve an unaudited consolidated net profit of approximately 115 million to 140 million HKD for the fiscal year ending September 30, 2025, marking a turnaround from losses, primarily due to the performance of listed equity investments [2] - Tianqi Lithium (09696.HK) has completed the construction of the third phase of its chemical-grade lithium concentrate expansion project and has officially commenced trial production [2] - Qingdao Port (06198.HK) plans to purchase two assets from the Qingdao Shipping Financial Center for the development of a cruise port [2] - CanSino Biologics (06185.HK) has initiated Phase I clinical trials for its DTCP–HIb–MCV4 combined vaccine and completed the enrollment of the first subject [2] - Fuhong Hanlin (02696.HK) received approval from the U.S. Food and Drug Administration for its application for the Phase I clinical trial of HLX18, a biosimilar to Nivolumab for the treatment of various solid tumors [2] - China National Nuclear Corporation (01763.HK) announced that its subsidiary, CNNC Haidewei, has received clinical approval for its BNCT boron drug [2] - Hisense Home Appliances (00921.HK) subscribed to a financial product from Jingu Trust for 1.892 billion yuan [2] Acquisition and Disposal - Evergrande Property (06666.HK) has received several updated non-binding offers from selected bidders, which the liquidators are currently considering [3] - Ruian Construction (00983.HK) has completed the sale of Ruian Property Management Services Co., Ltd. [4] - Tianjin Port Development (03382.HK) plans to purchase ten gantry cranes for 185 million yuan [5] Buyback Activities - Tencent Holdings (00700.HK) repurchased 1.036 million shares at a cost of 636 million HKD, with buyback prices ranging from 607 to 617 HKD [5] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for 152 million HKD, with buyback prices between 40.42 and 40.56 HKD [6] - COSCO Shipping Holdings (01919.HK) repurchased 3.9655 million shares for 53.6689 million HKD, with buyback prices ranging from 13.47 to 13.73 HKD [6] - Kuaishou-W (01024.HK) repurchased 755,000 shares for 49.9509 million HKD, with buyback prices between 65.4 and 66.6 HKD [7]

Core Viewpoint - China Nuclear Industry's subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has received approval for clinical trial application of its self-developed drug "Injection Boron [10B] Faron" for Boron Neutron Capture Therapy (BNCT), marking a significant advancement in cancer treatment [1] Group 1: Drug Development - The approved drug targets head and neck tumors that are resistant to radiotherapy and chemotherapy, particularly in cases that are recurrent, difficult to treat, infiltrative, and locally metastatic [1] - The treatment regimen is notably short, requiring only 1-2 sessions, and has low toxicity and side effects, representing a significant clinical advantage [1] Group 2: Innovation and Strategic Impact - The approval signifies a breakthrough in the collaborative research and development of BNCT drugs and devices, entering a new phase of clinical transformation [1] - This development aligns with the "Healthy China" strategy, injecting new momentum from nuclear technology into precision cancer treatment and contributing a "Chinese solution" to global cancer therapy [1]

智通财经APP讯，中国同辐(01763)发布公告，近日，国家药品监督管理局药品审评中心(CDE)官网信息 显示公司附属公司深圳市中核海得威生物科技有限公司(中核海得威)自主研发的2.2类改良新药"注射用 硼[B]法仑"(BNCT硼药：硼中子俘获疗法，Boron neutron capture therapy)临床试验申请获批(通知书编 号：2025LP03425)。 此外，中核海得威"注射用硼[B]法仑"临床试验申请获批标志着中核海得威BNCT药械协同研发领域取得 突破性成果，正式迈入临床转化新阶段，为"健康中国"战略下的精准肿瘤治疗注入核科技新动能，为全 球肿瘤治疗贡献"中国方案"。 中核海得威自研的国产"注射用硼[B]法仑"针对对放化疗不敏感、复发性、难治性、浸润性、中晚期、 局部转移的头颈部肿瘤具有显著临床优势，且治疗疗程短(仅需1-2次)、毒副作用低，代表了现代肿瘤精 准医学的发展方向和前沿创新，为患者提供了全新的治疗选择，推动了肿瘤治疗领域的创新与突破。 ...